Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer

NCT02664103 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02664103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02664103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2016
Completion date
November 6, 2017
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic